3 Charts That Show Why Aurinia Pharmaceuticals Stock Could Go Higher
Aurinia Pharmaceuticals (NASDAQ: AUPH) stock is without question one of the best-performing biotech stocks so far in 2017. Shares of the red-hot biotech have tripled in price year to date. Aurinia reported great results from a phase 2 study of experimental lupus nephritis drug voclosporin in March, causing the stock to skyrocket.
The big question for investors now, though, is: Can Aurinia Pharmaceuticals stock go even higher? Here are three charts that show the answer to that question is "yes" -- at least over the long term.
Image source: Getty Images.
Source: Fool.com
Aurinia Pharmaceuticals Inc. Stock
€4.89
3.170%
The community is currently still undecided about Aurinia Pharmaceuticals Inc. with 0 Buy predictions and 1 Sell predictions.
However, we have a potential of 104.71% for Aurinia Pharmaceuticals Inc. as the target price of 10 € is above the current price of 4.89 €.
